Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
复制标题
目前双膦酸盐在肿瘤学中的应用。
DOI：
--
复制
发表时间：
1998
影响因子：
45.3
通讯作者：
R. Rubens
中科院分区：
文献类型：
--
作者：
J. Body;R. Bartl;P. Burckhardt;P. Delmas;I. Diel;HA Fleisch;J. Kanis;R. Kyle;G. Mundy;A. Paterson;R. Rubens
目的
本文的目的是审查最近的数据，双膦酸盐在肿瘤学中的使用，并提供一些指导方针，其适应症用于癌症患者。
设计
专家们就双膦酸盐在癌症患者中使用的基本原理及其目前治疗晚期肿瘤引起的高钙血症和转移性骨痛的适应症以及预防多发性骨髓瘤和转移性骨病并发症达成的小组共识进行了综述。
结果
双膦酸盐是肿瘤诱导的破骨细胞介导的骨吸收的有效抑制剂。它们现在构成了癌症高钙血症的标准治疗方法，对此我们推荐1,500 mg氯膦酸盐或90 mg帕米膦酸盐的剂量;后一种化合物更有效，效果更持久。静脉注射双膦酸盐在转移性骨痛患者中发挥临床相关的镇痛作用。定期输注帕米膦酸二钠也可以达到国际抗癌联合会常规标准的部分客观反应，并提高化疗的客观反应率。在乳腺癌患者中，长期口服氯膦酸盐1,600 mg/d可使骨骼疾病的发生率降低1/4以上，而在化疗基础上每月输注90 mg帕米膦酸盐仅1年，可使所有骨骼相关事件的发生率降低1/3以上。使用双膦酸盐预防骨转移仍处于试验阶段。最后，在II期和III期多发性骨髓瘤患者中，双膦酸盐联合化疗上级优于单独化疗，可将骨骼发病率降低约一半。
结论
双膦酸盐的使用是转移性乳腺癌或多发性骨髓瘤引起的骨骼发病率管理的一个主要治疗进展，尽管许多问题仍然没有答案，特别是关于患者的最佳选择和治疗持续时间。
PURPOSE
The purpose of this article is to review the recent data on bisphosphonate use in oncology and to provide some guidelines on the indications for their use in cancer patients.
DESIGN
The group consensus reached by experts on the rationale for the use of bisphosphonates in cancer patients and their current indications for the treatment of tumor-induced hypercalcemia and metastatic bone pain in advanced disease and for the prevention of the complications of multiple myeloma and of metastatic bone disease are reviewed.
RESULTS
Bisphosphonates are potent inhibitors of tumor-induced osteoclast-mediated bone resorption. They now constitute the standard treatment for cancer hypercalcemia, for which we recommend a dose of 1,500 mg of clodronate or 90 mg of pamidronate; the latter compound is more potent and has a longer lasting effect. Intravenous bisphosphonates exert clinically relevant analgesic effects in patients with metastatic bone pain. Regular pamidronate infusions can also achieve a partial objective response by conventional International Union Against Cancer criteria and enhance the objective response rate to chemotherapy. In breast cancer, the prolonged administration of oral clodronate 1,600 mg daily reduces the frequency of morbid skeletal events by more than one fourth, whereas monthly pamidronate infusions of 90 mg for only 1 year in addition to chemotherapy reduce by more than one third the frequency of all skeletal-related events. The use of bisphosphonates to prevent bone metastases remains experimental. Last, bisphosphonates in addition to chemotherapy are superior to chemotherapy alone in patients with stages II and III multiple myeloma and can reduce the skeletal morbidity rate by approximately one half.
CONCLUSION
Bisphosphonate use is a major therapeutic advance in the management of the skeletal morbidity caused by metastatic breast cancer or multiple myeloma, although many questions remain unanswered, notably regarding the optimal selection of patients and the duration of treatment.
影响因子：
11.2
作者：
Kevin J. Cullen;Douglas Yee;William S. Sly;James F. Perdue;Brian Hampton;Marc E. Lippman;N. Rosen
通讯作者：
Kevin J. Cullen;Douglas Yee;William S. Sly;James F. Perdue;Brian Hampton;Marc E. Lippman;N. Rosen
双膦酸盐伊班膦酸盐和基质金属蛋白酶-2组织抑制剂联合治疗抑制乳腺癌溶骨性骨转移。
DOI：
10.1172/jci119435
发表时间：
1997
期刊：
The Journal of clinical investigation
影响因子：
--
作者：
Yoneda,T;Sasaki,A;Dunstan,C;Williams,PJ;Bauss,F;DeClerck,YA;Mundy,GR
通讯作者：
Mundy,GR